# Aclaris Therapeutics, Inc.: overview ACRS · Nasdaq · CIK 1557746 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/acrs.md) · [Financials](/companies/acrs/financials.md) · [Filings](/companies/acrs/filings.md) · [Insiders](/companies/acrs/insiders.md) Latest reported revenue: [$1.6m](/filings/0001104659-26-092065.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-092065). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.3](/filings/0001104659-25-107788.md) | [9.2 d](/filings/0001104659-26-020540.md) | [1.5](/filings/0001104659-26-057202.md) | [1.8](/filings/0001104659-26-092065.md) | [3.3](/filings/0001104659-25-107788.md) | [1.3 d](/filings/0001104659-26-020540.md) | [2.0](/filings/0001104659-26-057202.md) | [1.6](/filings/0001104659-26-092065.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(240.9%)](/filings/0001104659-25-107788.md) | [(1082.1%) d](/filings/0001104659-26-020540.md) | [(1242.9%)](/filings/0001104659-26-057202.md) | [(1035.9%)](/filings/0001104659-26-092065.md) | [(519.8%)](/filings/0001104659-25-107788.md) | [(1755.5%) d](/filings/0001104659-26-020540.md) | [(1111.8%)](/filings/0001104659-26-057202.md) | [(1487.9%)](/filings/0001104659-26-092065.md) | | Net margin | % | [(174.6%)](/filings/0001104659-25-107788.md) | [(1048.2%) d](/filings/0001104659-26-020540.md) | [(1036.8%)](/filings/0001104659-26-092065.md) | [(868.3%)](/filings/0001104659-26-092065.md) | [(443.0%)](/filings/0001104659-25-107788.md) | [(1528.6%) d](/filings/0001104659-26-020540.md) | [(993.2%)](/filings/0001104659-26-092065.md) | [(1320.1%)](/filings/0001104659-26-092065.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0001104659-25-107788.md) | not reported | [(0.12)](/filings/0001104659-26-057202.md) | [(0.13)](/filings/0001104659-26-092065.md) | [(0.12)](/filings/0001104659-25-107788.md) | not reported | [(0.15)](/filings/0001104659-26-057202.md) | [(0.15)](/filings/0001104659-26-092065.md) | | Free cash flow | $m | [22.0 d](/filings/0001104659-25-107788.md) | [(8.9) d](/filings/0001104659-26-020540.md) | [(13.1)](/filings/0001104659-26-057202.md) | [(10.0) d](/filings/0001104659-26-092065.md) | [(11.0) d](/filings/0001104659-25-107788.md) | [(13.2) d](/filings/0001104659-26-020540.md) | [(18.2)](/filings/0001104659-26-057202.md) | [(19.9) d](/filings/0001104659-26-092065.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.8](/filings/0001558370-24-001753.md) | [29.8](/filings/0001558370-24-001753.md) | [31.2](/filings/0001558370-25-001819.md) | [18.7](/filings/0001104659-26-020540.md) | [7.8](/filings/0001104659-26-020540.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1327.1%)](/filings/0001558370-24-001753.md) | [(302.0%)](/filings/0001558370-24-001753.md) | [(311.6%)](/filings/0001558370-25-001819.md) | [(758.2%)](/filings/0001104659-26-020540.md) | [(975.9%)](/filings/0001104659-26-020540.md) | | Net margin | % | [(1344.0%)](/filings/0001558370-24-001753.md) | [(292.1%)](/filings/0001558370-24-001753.md) | [(283.1%)](/filings/0001558370-25-001819.md) | [(705.5%)](/filings/0001104659-26-020540.md) | [(829.6%)](/filings/0001104659-26-020540.md) | | Diluted EPS | $ per share | [(1.60)](/filings/0001558370-24-001753.md) | [(1.33)](/filings/0001558370-24-001753.md) | [(1.27)](/filings/0001558370-25-001819.md) | [(1.71)](/filings/0001104659-26-020540.md) | [(0.53)](/filings/0001104659-26-020540.md) | | Free cash flow | $m | [(52.4)](/filings/0001558370-24-001753.md) | [(68.2)](/filings/0001558370-24-001753.md) | [(79.6)](/filings/0001558370-25-001819.md) | [(20.2)](/filings/0001104659-26-020540.md) | [(47.2)](/filings/0001104659-26-020540.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/acrs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $67.3m | 12,723,026 | | Added +5,918,954 | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $63.3m | 11,975,000 | | Reduced −2,275,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $53.1m | 10,037,008 | | Added +2,629,943 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $49.4m | 9,345,000 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $35.4m | 6,694,637 | | Added +27,971 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $30.8m | 5,817,866 | | Added +650,397 | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $26.1m | 4,925,374 | | Unchanged | | [Rock Springs Capital Management LP](/funds/1595725.md) | 2026-06-30 | $22.9m | 4,330,532 | | Reduced −142,118 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $21.5m | 4,071,000 | | Added +200,000 | | [Decheng Capital LLC](/funds/2010850.md) | 2026-06-30 | $21.4m | 4,041,736 | | Unchanged | ## Recent filings [All 859 filings](/companies/acrs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 17:25 ET | [8-K](/filings/0001104659-26-119231.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-119231 | | 2026-10-27 | 06:06 ET | [8-K](/filings/0001104659-26-118952.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-118952 | | 2026-08-06 | 17:15 ET | [8-K](/filings/0001104659-26-092128.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-092128 | | 2026-08-06 | 16:31 ET | [10-Q](/filings/0001104659-26-092065.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092065 | | 2026-08-06 | 07:15 ET | [8-K](/filings/0001104659-26-091629.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-091629 | | 2026-06-04 | 16:01 ET | [8-K](/filings/0001104659-26-070494.md) | 5.07 Shareholder vote results | 0001104659-26-070494 | | 2026-05-07 | 16:32 ET | [10-Q](/filings/0001104659-26-057202.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057202 | | 2026-05-07 | 07:15 ET | [8-K](/filings/0001104659-26-056669.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-056669 | | 2026-04-28 | 06:45 ET | [8-K](/filings/0001104659-26-049733.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-049733 | | 2026-04-23 | 07:45 ET | [DEF 14A](/filings/0001104659-26-047262.md) | Proxy statement, period 2026-06-04 | 0001104659-26-047262 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-020540.md), filed Feb 26, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested. [See the target](/leagues/2026q3/targets/7e48f80f-a721-4206-b2eb-61ca251b4922) ## About the filer - CIK: 1557746 - Tickers: ACRS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:27 ET. No prices; not investment advice.